

# Andrew Blauvelt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3656879/publications.pdf>

Version: 2024-02-01

324  
papers

24,627  
citations

8755

75  
h-index

8630

146  
g-index

365  
all docs

365  
docs citations

365  
times ranked

15234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2022, 33, 848-856.	2.2	25
2	Efficacy, safety, usability, and acceptability of risankizumab 150mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2085-2093.	2.2	7
3	Tyrosine kinase 2 and Janus kinase signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 148-157.	1.2	51
4	Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 581-589.	1.2	15
5	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	2.2	17
6	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*. <i>British Journal of Dermatology</i> , 2022, 186, 466-475.	1.5	41
7	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 827-834.	1.2	33
8	Lymphatic Dysfunction Exacerbates Cutaneous Tumorigenesis and Psoriasis-Like Skin Inflammation through Accumulation of Inflammatory Cytokines. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1692-1702.e3.	0.7	3
9	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. <i>Dermatology and Therapy</i> , 2022, 12, 223-231.	3.0	7
10	Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data. <i>Pediatric Dermatology</i> , 2022, 39, 187-196.	0.9	23
11	Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year. <i>Dermatology and Therapy</i> , 2022, 12, 9-13.	3.0	0
12	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 727-740.	3.0	9
13	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800.	3.0	6
14	A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab. <i>Dermatology and Therapy</i> , 2022, 12, 701-714.	3.0	9
15	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETIK PSO-1 and PSO-2 Trials. <i>SKIN the Journal of Cutaneous Medicine</i> , 2022, 6, s4.	0.3	3
16	Clinical and Serological Characterization of Orf-Induced Immunobullous Disease. <i>JAMA Dermatology</i> , 2022, 158, 670.	4.1	8
17	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2022, 12, 911.	3.0	4
18	Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. <i>Dermatology and Therapy</i> , 2022, 12, 195-202.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study. <i>Journal of Drugs in Dermatology</i> , 2022, 21, 399-407.	0.8	3
20	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). <i>American Journal of Clinical Dermatology</i> , 2022, 23, 365-383.	6.7	30
21	Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases. <i>Advances in Therapy</i> , 2022, 39, 3214-3224.	2.9	7
22	Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings. <i>Journal of Medical Economics</i> , 2022, 25, 741-749.	2.1	1
23	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2022, 12, 1431-1446.	3.0	7
24	Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2605-2613.	2.2	2
25	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.5	17
26	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 360-368.	1.2	37
27	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 135-142.	2.4	29
28	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*. <i>British Journal of Dermatology</i> , 2021, 184, 270-280.	1.5	29
29	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.5	16
30	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial*. <i>British Journal of Dermatology</i> , 2021, 184, 50-59.	1.5	119
31	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.5	15
32	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. <i>British Journal of Dermatology</i> , 2021, 184, 437-449.	1.5	289
33	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*. <i>British Journal of Dermatology</i> , 2021, 184, 1047-1058.	1.5	58
34	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 417-421.	2.4	11
35	Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 84-94.	0.9	5
36	Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, s21.	0.3	1

#	ARTICLE	IF	CITATIONS
37	How to Best Define Psoriasis Severity: A New Consensus Statement From the International Psoriasis Council. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 6-7.	0.7	0
38	Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. <i>New England Journal of Medicine</i> , 2021, 384, 512-520.	27.0	82
39	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	13.7	139
40	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021, 397, 475-486.	13.7	136
41	Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). <i>BioDrugs</i> , 2021, 35, 229-238.	4.6	8
42	Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e354-e355.	2.4	2
43	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1212-1223.e6.	3.8	31
44	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
45	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021, 397, 2151-2168.	13.7	259
46	PBI17 Comparison of Switching Patterns Among Patients with Psoriasis Using Ixekizumab or Secukinumab in Real-World Settings. <i>Value in Health</i> , 2021, 24, S17-S18.	0.3	0
47	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1707-1718.e9.	0.7	62
48	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 130-141.	27.0	114
49	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	27.0	173
50	Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. <i>ACR Open Rheumatology</i> , 2021, 3, 501-511.	2.1	4
51	An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e828-e831.	2.4	1
52	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2398-2408.	2.4	4
53	Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. <i>British Journal of Dermatology</i> , 2021, 185, 1264-1265.	1.5	4
54	24916 Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: Pooled analysis from two randomized phase 3 studies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, AB50.	1.2	2

#	ARTICLE	IF	CITATIONS
55	26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE). Journal of the American Academy of Dermatology, 2021, 85, AB120.	1.2	0
56	27454 Efficacy and safety of long-term risankizumab re-treatment following drug withdrawal: IMMhance trial. Journal of the American Academy of Dermatology, 2021, 85, AB144.	1.2	0
57	25750 Tapinarof cream 1% once daily for plaque psoriasis: Secondary efficacy outcomes from two pivotal phase 3 trials. Journal of the American Academy of Dermatology, 2021, 85, AB69.	1.2	2
58	27476 Increased benefit of secukinumab vs ustekinumab in patients with psoriasis regardless of previous systemic psoriasis therapy: Pooled analysis of the phase 3 CLEAR and CLARITY trials. Journal of the American Academy of Dermatology, 2021, 85, AB147.	1.2	0
59	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157, 1047.	4.1	236
60	27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study. Journal of the American Academy of Dermatology, 2021, 85, AB143.	1.2	1
61	27043 Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1. Journal of the American Academy of Dermatology, 2021, 85, AB127.	1.2	0
62	26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD). Journal of the American Academy of Dermatology, 2021, 85, AB97.	1.2	0
63	25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1. Journal of the American Academy of Dermatology, 2021, 85, AB80.	1.2	0
64	28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.2	0
65	28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). Journal of the American Academy of Dermatology, 2021, 85, AB177.	1.2	1
66	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology, 2021, 141, 2328-2337.	0.7	21
67	Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). SKIN the Journal of Cutaneous Medicine, 2021, 5, s15.	0.3	3
68	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology, 2021, 22, 101-115.	6.7	32
69	Bimekizumab for the Treatment of Psoriasis. Drugs, 2021, 81, 1751-1762.	10.9	18
70	Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months. Dermatology and Therapy, 2021, 11, 2133-2145.	3.0	3
71	Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN the Journal of Cutaneous Medicine, 2021, 5, s35.	0.3	3
72	Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2. Journal of Drugs in Dermatology, 2021, 20, 855-860.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. <i>Journal of Dermatological Treatment</i> , 2020, 31, 141-146.	2.2	9
74	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.5	103
75	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020, 182, 180-189.	1.5	22
76	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	1.2	155
77	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 117-122.	1.2	120
78	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). <i>British Journal of Dermatology</i> , 2020, 182, 1120-1135.	1.5	92
79	Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. <i>British Journal of Dermatology</i> , 2020, 182, 880-888.	1.5	20
80	Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 927-935.	1.2	41
81	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 44.	4.1	297
82	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 1484-1487.	1.5	2
83	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020, 182, 1359-1368.	1.5	20
84	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1138-1149.	1.2	37
85	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
86	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	1.2	71
87	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 119-131.	6.7	56
88	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
89	Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e303-e304.	1.2	2
90	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. <i>Dermatology and Therapy</i> , 2020, 10, 1415-1421.	3.0	6

#	ARTICLE	IF	CITATIONS
91	15984 Psoriasis patients treated with ixekizumab were maintained longer on monotherapy compared with other biologics in real-world clinical practice settings: Results from IBM MarketScan databases. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB52.	1.2	1
92	14998 Reductions in absolute PASI over 144 weeks of treatment with certolizumab pegol in patients with plaque psoriasis: Pooled analysis from two phase 3 trials (CIMPASI-1 and CIMPASI-2). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB138.	1.2	0
93	15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB141.	1.2	1
94	15277 Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB145.	1.2	0
95	14162 Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB131.	1.2	0
96	15807 Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB160.	1.2	1
97	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
98	COVID-19 and Psoriasis: New Guidance From the NPF. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 127-128.	0.7	0
99	ixekizumab vs guselkumab in patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 3 trial. <i>British Journal of Dermatology</i> , 2020, 182, e208.	1.5	0
100	Tildrakizumab vs ixekizumab in patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 3 trial. <i>British Journal of Dermatology</i> , 2020, 182, e208.	1.5	0
101	Dupilumab vs dupilumab in patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 3 trial. <i>British Journal of Dermatology</i> , 2020, 182, e208.	1.5	0
102	A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, e193.	1.5	1
103	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1367-1374.	1.2	48
104	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	6.7	78
105	Assessing the need for routine safety testing for patients being treated with dupilumab for moderate to severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2020, 182, e186-e209.	1.5	4
106	A study of the drug tildrakizumab for plaque psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, e196.	1.5	0
107	Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 517-527.	1.8	22
108	A study of the drug tildrakizumab in psoriasis patients. <i>British Journal of Dermatology</i> , 2020, 182, e100.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Ä€É1âœ“é“¶â±ç—...æ,Éè€...äâ¼€â±çš,, tildrakizumab èç%©ç”ç©¶. British Journal of Dermatology, 2020, 182, 13-13.		0
110	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2020, 156, 411.	4.1	241
111	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). Journal of Investigative Dermatology, 2020, 140, 1784-1793.e2.	0.7	61
112	æœ%åšâ°“äœ¼/4€âç”ÿç%©â~¶â%, tildrakizumab çš,,æš—èæš—ä½“, ä»¥âšèç™â-1â...¶æ²»ç—æœ%æ•æ€šâšç”ÿâ“âœ¼/2±â“: Br		
113	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2020, 156, 649.	4.1	120
114	Bimekizumab. Current Dermatology Reports, 2020, 9, 36-42.	2.1	2
115	Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. SKIN the Journal of Cutaneous Medicine, 2020, 4, s82.	0.3	2
116	Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. SKIN the Journal of Cutaneous Medicine, 2020, 4, s83.	0.3	2
117	Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2). SKIN the Journal of Cutaneous Medicine, 2020, 4, s96.	0.3	4
118	Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. Journal of Drugs in Dermatology, 2020, 19, 487-492.	0.8	10
119	Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes. Journal of Drugs in Dermatology, 2020, 19, 487-492.	0.8	5
120	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2019, 81, 1405-1409.	1.2	14
121	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839.	13.7	250
122	Ixekizumab—An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 180-185.	0.7	3
123	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2305-2312.	2.4	40
124	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open, 2019, 5, e000942.	3.8	45
125	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American Journal of Clinical Dermatology, 2019, 20, 863-871.	6.7	29
126	Predicting Clinical Responses to Ustekinumab. JAMA Dermatology, 2019, 155, 1227.	4.1	1



#	ARTICLE	IF	CITATIONS
127	Brodalumab in patients who had inadequate response to ustekinumab. <i>British Journal of Dermatology</i> , 2019, 180, e40-e40.	1.5	0
128	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1733-1741.	2.4	20
129	Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. <i>Arthritis Research and Therapy</i> , 2019, 21, 111.	3.5	215
130	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	2.4	19
131	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.5	288
132	Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 196-197.	1.5	28
133	Brodalumab ç”“äŽâ¹¹Ĉĕā¥’ā•æŠ—ā” ç”ä,è³çš,,æ,£èĈ.... <i>British Journal of Dermatology</i> , 2019, 180, e53-e53.	1.5	0
134	Dupilumab ä,â°Šè~é³Ĉĕä,çš,,ç»“è†œç,Ž. <i>British Journal of Dermatology</i> , 2019, 181, e81.	1.5	0
135	Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 1366-1376.	0.9	13
136	Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 158-167.e1.	1.2	99
137	Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. <i>British Journal of Dermatology</i> , 2019, 180, 306-314.	1.5	25
138	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 546-552.	2.4	29
139	Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1) Tj ETQq1 1 0.784314.2gBT /Over	1.2	10
140	Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2019, 18, 297-299.	0.8	4
141	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1515-1522.	2.4	19
142	Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. <i>Drugs</i> , 2018, 78, 463-478.	10.9	169
143	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and) Tj ETQq1 1 0.784314.2gBT /Over	1.2	10
144	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 294-301.e6.	1.2	22

#	ARTICLE	IF	CITATIONS
145	British Journal of Dermatology, 2018, 178, 1315-1323.		
146	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology, 2018, 79, 266-276.e5.	1.2	117
147	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology, 2018, 79, 277-286.e10.	1.2	163
148	Developing drugs for treatment of atopic dermatitis in children (<math>\geq</math>3 months to <math>\leq</math>18 years of age): Draft guidance for industry. Pediatric Dermatology, 2018, 35, 303-322.	0.9	16
149	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). British Journal of Dermatology, 2018, 178, 1315-1323.	1.5	44
150	Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis. , 2018, , 123-131.		3
151	Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. Journal of Investigative Dermatology, 2018, 138, 1973-1981.	0.7	45
152	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. Journal of the American Academy of Dermatology, 2018, 78, 741-748.	1.2	22
153	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. Journal of the American Academy of Dermatology, 2018, 78, 81-89.e5.	1.2	121
154	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 2018, 178, 674-681.	1.5	80
155	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. British Journal of Dermatology, 2018, 178, 132-139.	1.5	57
156	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. Journal of Dermatological Treatment, 2018, 29, 220-229.	2.2	14
157	Ixekizumab efficacy and safety in moderate-to-severe genital psoriasis. British Journal of Dermatology, 2018, 179, e177-e177.	1.5	0
158	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. Journal of the American Association of Nurse Practitioners, 2018, 30, 529-541.	0.9	11
159	British Journal of Dermatology, 2018, 179, e179-e179.		
160	Response to critical appraisal of LIBERTY AD CHRONOS. British Journal of Dermatology, 2018, 179, 1423-1423.	1.5	1
161	Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatology and Therapy, 2018, 8, 571-579.	3.0	59
162	Authors' Reply to Pires et al.: Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs, 2018, 78, 853-855.	10.9	3

#	ARTICLE	IF	CITATIONS
163	Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 869-877.	1.2	32
164	Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2168-2173.	0.7	41
165	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.5	57
166	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 844-852.	1.5	87
167	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 379-390.	6.5	447
168	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	13.7	457
169	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. <i>JAMA Dermatology</i> , 2018, 154, 676.	4.1	90
170	Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. <i>British Journal of Dermatology</i> , 2018, 179, 623-631.	1.5	112
171	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 200-206.	0.8	15
172	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 826-832.	0.8	31
173	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	1.2	673
174	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	6.7	29
175	IL-6 Differs from TNF- $\alpha$ : Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 541-542.	0.7	36
176	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1004-1013.	2.4	52
177	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017, 376, 1551-1560.	27.0	413
178	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 879-881.	1.5	26
179	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	13.7	884
180	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) <i>Lancet, The</i> , 2017, 389, 2287-2303.	13.7	428

#	ARTICLE	IF	CITATIONS
181	Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). <i>British Journal of Dermatology</i> , 2017, 177, 1552-1561.	1.5	44
182	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1537-1551.	1.5	43
183	Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1693-1699.	2.4	18
184	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1483-1490.	2.4	33
185	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017, 177, 587-590.	1.5	10
186	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 855-862.	1.2	104
187	398 Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3). <i>Journal of Investigative Dermatology</i> , 2017, 137, S260.	0.7	4
188	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 372-374.	1.2	45
189	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1495-1502.	1.5	48
190	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 752-758.	1.5	47
191	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 60-69.e9.	1.2	258
192	Biosimilars for psoriasis: clinical studies to determine similarity. <i>British Journal of Dermatology</i> , 2017, 177, 23-33.	1.5	16
193	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. <i>British Journal of Dermatology</i> , 2016, 174, 282-286.	1.5	38
194	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	1.2	264
195	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 77-82.e7.	1.2	96
196	A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1513-1515.	0.7	9
197	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2016, 375, 2335-2348.	27.0	1,467
198	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 273-286.	1.5	378

#	ARTICLE	IF	CITATIONS
199	Safety of secukinumab in the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1413-1420.	2.4	99
200	A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 329-336.	6.7	39
201	Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 506-515.	1.2	132
202	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2016, 375, 345-356.	27.0	670
203	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 255-263.	3.1	18
204	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet</i> , The, 2016, 387, 40-52.	13.7	471
205	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
206	Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 1226-1234.	0.8	26
207	A boxed warning for inadequate psoriasis treatment. <i>Cutis</i> , 2016, 98, 206-207.	0.3	0
208	Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 563.	1.8	25
209	Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB167.	2.9	8
210	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	1.2	472
211	IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1946-1953.	0.7	68
212	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). <i>British Journal of Dermatology</i> , 2015, 172, 484-493.	1.5	279
213	A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. <i>Clinical Rheumatology</i> , 2015, 34, 1745-1751.	2.2	14
214	Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. <i>Oncotarget</i> , 2015, 6, 18081-18093.	1.8	41
215	Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 805-12.	0.8	10
216	Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2015, 14, 821-33.	0.8	40

#	ARTICLE	IF	CITATIONS
217	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 168-177.	1.2	135
218	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1176-1182.	1.2	100
219	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, S5-S22.	0.1	0
220	Antimicrobial Peptide LL-37 Produced by HSV-2-Infected Keratinocytes Enhances HIV Infection of Langerhans Cells. <i>Cell Host and Microbe</i> , 2013, 13, 77-86.	11.0	56
221	Oral Administration of the CCR5 Inhibitor, Maraviroc, Blocks HIV Ex Vivo Infection of Langerhans Cells within the Epithelium. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2803-2805.	0.7	7
222	Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction. <i>Journal of Leukocyte Biology</i> , 2013, 94, 137-145.	3.3	25
223	Implications for Biologic Therapy: <i>Staphylococcus aureus</i> Decolonization of Individuals With a History of Recurrent Skin and Soft-Tissue Infections. <i>JAMA Dermatology</i> , 2013, 149, 986.	4.1	2
224	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013, 6, S2-S20.	0.1	17
225	Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 874-80.	0.8	17
226	Lymphatic Dysfunction Impairs Antigen-Specific Immunization, but Augments Tissue Swelling Following Contact with Allergens. <i>Journal of Investigative Dermatology</i> , 2012, 132, 667-676.	0.7	20
227	The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 642-650.	1.2	52
228	Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95.	1.4	148
229	Kaposi's sarcoma and human dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus express CCL21. <i>Journal of Dermatological Science</i> , 2011, 61, 139-142.	1.9	0
230	Blocking MAPK Signaling Downregulates CCL21 in Lymphatic Endothelial Cells and Impairs Contact Hypersensitivity Responses. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1927-1935.	0.7	8
231	IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A. <i>Journal of Immunology</i> , 2011, 186, 1495-1502.	0.8	212
232	Papillary thyroid carcinoma in a patient with severe psoriasis receiving adalimumab. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 999-1000.	1.2	4
233	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. <i>Psoriasis Forum</i> , 2011, 17a, 119-130.	0.1	0
234	IL-17 is essential for host defense against cutaneous <i>Staphylococcus aureus</i> infection in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 1762-1773.	8.2	554

#	ARTICLE	IF	CITATIONS
235	IL-23 and IL-17A, but Not IL-12 and IL-22, Are Required for Optimal Skin Host Defense against <i>Candida albicans</i> . <i>Journal of Immunology</i> , 2010, 185, 5453-5462.	0.8	193
236	Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 1058-1069.	1.2	102
237	Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1373-1383.	0.7	522
238	Sequelae of World War II: An Outbreak of Chronic Cutaneous Nontuberculous Mycobacterial Infection among Satowanese Islanders. <i>Clinical Infectious Diseases</i> , 2009, 48, 1541-1546.	5.8	13
239	Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2175-2183.	0.7	410
240	Inflammatory Skin Disease in K5.hTGF- $\beta$ 1 Transgenic Mice Is Not Dependent on the IL-23/Th17 Inflammatory Pathway. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2443-2450.	0.7	24
241	Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation. <i>Blood</i> , 2009, 113, 5157-5166.	1.4	60
242	T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1064-1067.	0.7	138
243	Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1173-1181.	0.7	39
244	Orf-induced immunobullous disease: A distinct autoimmune blistering disorder. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 49-55.	1.2	42
245	Significant Virus Replication in Langerhans Cells following Application of HIV to Abraded Skin: Relevance to Occupational Transmission of HIV. <i>Journal of Immunology</i> , 2008, 180, 3297-3304.	0.8	47
246	New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF- $\beta$ 1. <i>Expert Review of Dermatology</i> , 2007, 2, 69-78.	0.3	48
247	Efalizumab for severe atopic dermatitis: A pilot study in adults. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 222-227.	1.2	88
248	C34, a Membrane Fusion Inhibitor, Blocks HIV Infection of Langerhans Cells and Viral Transmission to T Cells. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1436-1443.	0.7	19
249	Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. <i>Current Rheumatology Reports</i> , 2007, 9, 461-467.	4.7	334
250	Histone Deacetylase Inhibitors Induce Apoptosis with Minimal Viral Reactivation in Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2516-2524.	0.7	10
251	Oncostatin M Enhances CCL21 Expression by Microvascular Endothelial Cells and Increases the Efficiency of Dendritic Cell Trafficking to Lymph Nodes. <i>Journal of Immunology</i> , 2006, 177, 7665-7672.	0.8	40
252	Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter. <i>Blood</i> , 2005, 105, 2356-2363.	1.4	35

#	ARTICLE	IF	CITATIONS
253	Cutaneous diseases. , 2005, , 413-430.		0
254	The role of Langerhans cells in the sexual transmission of HIV. <i>Journal of Dermatological Science</i> , 2005, 40, 147-155.	1.9	70
255	Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. <i>Science</i> , 2004, 306, 485-487.	12.6	364
256	HIV-Infected Langerhans Cells Preferentially Transmit Virus to Proliferating Autologous CD4+Memory T Cells Located within Langerhans Cell-T Cell Clusters. <i>Journal of Immunology</i> , 2004, 172, 2219-2224.	0.8	59
257	PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes. <i>Journal of Virology</i> , 2004, 78, 7602-7609.	3.4	64
258	In This Issueâ€”Full Court Press on Psoriasis. <i>Journal of Investigative Dermatology</i> , 2004, 123, vii-viii.	0.7	2
259	Rapid publication for selected JAAD articles. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 299-300.	1.2	1
260	Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 533-540.	1.2	61
261	Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. <i>Journal of Clinical Investigation</i> , 2004, 113, 701-708.	8.2	231
262	Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. <i>Dermatologic Clinics</i> , 2003, 21, 301-309.	1.7	29
263	11. Allergic and immunologic diseases of the skin. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, S560-S570.	2.9	64
264	Decreased Stimulation of CD4+T Cell Proliferation and IL-2 Production by Highly Enriched Populations of HIV-Infected Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 4260-4266.	0.8	71
265	Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C. <i>Journal of Virology</i> , 2003, 77, 1021-1038.	3.4	189
266	Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Prolongs the Life Span of Primary Human Umbilical Vein Endothelial Cells. <i>Journal of Virology</i> , 2003, 77, 6188-6196.	3.4	81
267	R5 HIV productively infects Langerhans cells, and infection levels are regulated by compoundCCR5polymorphisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8401-8406.	7.1	177
268	Stromal-Derived Factor 1 Expression in the Human Thymus. <i>Journal of Immunology</i> , 2002, 168, 2609-2617.	0.8	37
269	Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10. <i>Archives of Dermatology</i> , 2002, 138, 1341-6.	1.4	61
270	Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 512-518.	1.2	237



#	ARTICLE	IF	CITATIONS
271	The future of academic dermatology in the United States: Report on the resident retreat for future physician-scientists, June 15-17, 2001. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 300-303.	1.2	21
272	Minimal reactivation of Kaposi's sarcoma-associated herpesvirus by corticosteroids in latently infected B cell lines. <i>Journal of Medical Virology</i> , 2002, 66, 378-383.	5.0	14
273	Pityriasis Rosea is Associated with Systemic Active Infection with Both Human Herpesvirus-7 and Human Herpesvirus-6. <i>Journal of Investigative Dermatology</i> , 2002, 119, 793-797.	0.7	149
274	In "That" Issue. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1.	0.7	0
275	Essential Roles for Dendritic Cells in the Pathogenesis and Potential Treatment of HIV Disease. <i>Journal of Investigative Dermatology</i> , 2002, 119, 365-369.	0.7	67
276	Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001, 97, 3244-3250.	1.4	220
277	Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001, 97, 2374-2380.	1.4	54
278	Rationale for testing chemokine inhibitors (Virustats) for prevention of HIV-1 transmission.. <i>Aids</i> , 2001, 15, S57-S58.	2.2	0
279	Skin Diseases Associated with Human Herpesvirus 6, 7, and 8 Infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 197-202.	0.8	34
280	Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF- $\beta$ 1 and increased viral replication with CD40 ligand-induced maturation. <i>European Journal of Immunology</i> , 2001, 31, 360-368.	2.9	45
281	Ex vivo HIV-1 infection of human immature langerhans cells within epithelial tissue explants: a novel model for sexual transmission of HIV-1. <i>Aids</i> , 2001, 15, S40.	2.2	0
282	Human skin Langerhans cells are targets of dengue virus infection. <i>Nature Medicine</i> , 2000, 6, 816-820.	30.7	586
283	Morphogenesis of HHV8 in Primary Human Dermal Microvascular Endothelium and Primary Effusion Lymphomas. <i>Ultrastructural Pathology</i> , 2000, 24, 291-300.	0.9	10
284	HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. <i>Aids</i> , 2000, 14, 647-651.	2.2	42
285	Candidate Microbicides Block HIV-1 Infection of Human Immature Langerhans Cells within Epithelial Tissue Explants. <i>Journal of Experimental Medicine</i> , 2000, 192, 1491-1500.	8.5	151
286	Widespread cutaneous vascular papules associated with peripheral blood eosinophilia and prominent inguinal lymphadenopathy. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 698-700.	1.2	6
287	Variant genotypes of Fc $\gamma$ RIIIA influence the development of Kaposi's sarcoma in HIV-infected men. <i>Blood</i> , 2000, 95, 2386-90.	1.4	29
288	An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. <i>Blood</i> , 2000, 96, 2562-7.	1.4	35

#	ARTICLE	IF	CITATIONS
289	Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. <i>European Journal of Immunology</i> , 1999, 29, 2551-2559.	2.9	151
290	Human Herpesvirus 6 Infects Dendritic Cells and Suppresses Human Immunodeficiency Virus Type 1 Replication in Coinfected Cultures. <i>Journal of Virology</i> , 1999, 73, 4019-4028.	3.4	43
291	Identification and Rapid Quantification of Early- and Late-Lytic Human Herpesvirus 8 Infection in Single Cells by Flow Cytometric Analysis: Characterization of Antiherpesvirus Agents. <i>Journal of Virology</i> , 1999, 73, 5894-5902.	3.4	53
292	Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. <i>Journal of Immunology</i> , 1999, 163, 1666-73.	0.8	49
293	Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen-processing compartments. <i>Journal of Immunology</i> , 1999, 163, 5435-43.	0.8	40
294	HIV-dendritic cell interactions promote efficient viral infection of T cells. <i>Journal of Biomedical Science</i> , 1998, 5, 253-259.	7.0	34
295	No Evidence of Human Herpesvirus 8 Infection in Patients with Paraneoplastic Pemphigus, Pemphigus Vulgaris, or Pemphigus Foliaceus. <i>Journal of Investigative Dermatology</i> , 1998, 111, 781-783.	0.7	33
296	Cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells. <i>Journal of Immunology</i> , 1998, 161, 3219-23.	0.8	43
297	Propagation of a Human Herpesvirus from AIDS-Associated Kaposi's Sarcoma. <i>New England Journal of Medicine</i> , 1997, 336, 1837-1839.	27.0	16
298	Human Herpesvirus 8 Infection Occurs following Adolescence in the United States. <i>Journal of Infectious Diseases</i> , 1997, 176, 771-774.	4.0	80
299	Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. <i>Aids</i> , 1997, 11, F35-F45.	2.2	197
300	HIV-related eosinophilic folliculitis: a panel discussion. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1997, 16, 219-223.	1.6	29
301	Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection. <i>Nature Medicine</i> , 1997, 3, 1369-1375.	30.7	396
302	Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.. <i>Journal of Clinical Investigation</i> , 1997, 100, 2043-2053.	8.2	185
303	UVB Induces IL-12 Transcription in Human Keratinocytes <i>in vivo</i> and <i>in vitro</i> . <i>Photochemistry and Photobiology</i> , 1996, 63, 854-859.	2.5	40
304	Interleukin-15 mRNA Is Expressed by Human Keratinocytes, Langerhans Cells, and Blood-Derived Dendritic Cells and Is Downregulated by Ultraviolet B Radiation. <i>Journal of Investigative Dermatology</i> , 1996, 106, 1047-1052.	0.7	111
305	Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12.. <i>Journal of Clinical Investigation</i> , 1996, 97, 1550-1555.	8.2	37
306	Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. <i>Archives of Dermatology</i> , 1996, 132, 1503-4.	1.4	5

#	ARTICLE	IF	CITATIONS
307	The Skin as Target, Vector, and Effector Organ in Human Immunodeficiency Virus Disease. <i>Journal of Investigative Dermatology</i> , 1995, 105, S122-S126.	0.7	17
308	Human Langerhans Cells Express E-Cadherin. <i>Journal of Investigative Dermatology</i> , 1995, 104, 293-296.	0.7	74
309	Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. <i>Journal of Immunology</i> , 1995, 154, 4851-6.	0.8	127
310	Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. <i>Archives of Dermatology</i> , 1995, 131, 360-1.	1.4	3
311	Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. <i>Journal of Immunology</i> , 1995, 154, 3506-15.	0.8	56
312	Gianotti-Crosti syndrome and human immunodeficiency virus infection. <i>Archives of Dermatology</i> , 1994, 130, 481-3.	1.4	3
313	WIDESPREAD PRIMARY CUTANEOUS INFECTION WITH MYCOBACTERIUM FORTUITUM. <i>International Journal of Dermatology</i> , 1993, 32, 512-514.	1.0	38
314	Human papillomavirus DNA in the dermis of condyloma acuminatum. <i>Journal of Cutaneous Pathology</i> , 1993, 20, 447-450.	1.3	3
315	Identification of Mycobacterium tuberculosis DNA in five different types of cutaneous lesions by the polymerase chain reaction. <i>Archives of Dermatology</i> , 1993, 129, 1594-8.	1.4	3
316	Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro with liquid nitrogen, trichloroacetic acid, and podophyllin. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 710-714.	1.2	20
317	Basal cell carcinoma of the scrotum. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 574-578.	1.2	49
318	Human papillomavirus type 6 infection involving cutaneous nongenital sites. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 876-879.	1.2	17
319	PORPHYRIA CUTANEA TARDA AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION. <i>International Journal of Dermatology</i> , 1992, 31, 474-479.	1.0	56
320	CUTANEOUS CRYPTOCOCCOSIS MIMICKING KAPOSIS SARCOMA AS THE INITIAL MANIFESTATION OF DISSEMINATED DISEASE. <i>International Journal of Dermatology</i> , 1992, 31, 279-280.	1.0	16
321	Pityriasis rubra pilaris and HIV infection. <i>Journal of the American Academy of Dermatology</i> , 1991, 24, 703-705.	1.2	57
322	Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. <i>Archives of Dermatology</i> , 1991, 127, 1159-66.	1.4	10
323	Long-term radiographic follow-up after isotretinoin therapy. <i>Journal of the American Academy of Dermatology</i> , 1988, 18, 1252-1261.	1.2	39
324	Cutaneous diseases. , 0, , 473-502.		0